Lung Neoplasms: all 7,334 studies

Page 39 of 74. Open to participants first (1,555), then studies with results posted, then the rest; newest registration first within each.

• Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II TrialStatus unknownNCT04553887Phase 2
• Navigation Endobronchial UltrasoundCompletedNCT04553809Not applicable
• Safety of Lung Cryobiopsy in People With CancerCompletedNCT04548830Phase 2
• Resistance to Oral Therapy in Lung CancerCompletedNCT04546282
• Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib ResistanceActive, not recruitingNCT04545710Phase 2
• Prediction of Esophageal and Lung Toxicities After Radiation (Chemo) TherapyCompletedNCT04545658
• A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesCompletedNCT04544748Phase 1
• Venetoclax and Irinotecan in Relapsed/Refractory SCLCWithdrawnNCT04543916Phase 1/2
• Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLCStatus unknownNCT04541251Phase 2
• Impact on Quality of Life From Multi-modality Lung CancerStatus unknownNCT04540757
• Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER CancerCompletedNCT04540081Not applicable
• Impact of COVID-19 on Lung Cancer PatientsCompletedNCT04538456
• PCI for Patients With ES-SCLC After RCT:a Prospective Randomized StudyStatus unknownNCT04535739Phase 3
• Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived ExosomeStatus unknownNCT04529915
• The Efficacy of Intraoperative Pulmonary Nodules Localization Guided by Virtual Reality TechnologyWithdrawnNCT04529603Not applicable
• Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLCStatus unknownNCT04524299Phase 2
• PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)TerminatedNCT04524195Phase 1
• Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIsStatus unknownNCT04519983Phase 2
• Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical StudyStatus unknownNCT04517526Phase 2
• Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain MetastasisActive, not recruitingNCT04516070Phase 2
• Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical StudyStatus unknownNCT04513301Phase 2
• Significance of Early Mobilization After VATS-LCompletedNCT04508270
• Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
• NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung CancerActive, not recruitingNCT04505267Phase 1
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
• Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung CancerApproved for marketingNCT04504513
• Rehabilitation for Thoracoscopic LobectomyCompletedNCT04502654
• Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)CompletedNCT04501497
• A Study of Gimatecan (ST1481) in Small Cell Lung CancerStatus unknownNCT04501029Phase 2
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence TherapyCompletedNCT04500535
• Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung CancerStatus unknownNCT04500145Phase 3
• Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the LungTerminatedNCT04496674Phase 1/2
• CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCActive, not recruitingNCT04495153Phase 2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
• Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.Status unknownNCT04490421Phase 3
• Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung CancerStatus unknownNCT04487093Phase 1
• Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT04486287Phase 2
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• Detection and Volumetry of Pulmonary Nodules on Ultra-low Dose Chest CT Scan With Deeplearning Image Reconstruction Algorithm (DLIR)CompletedNCT04482114Not applicable
• Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedNCT04479306Phase 1
• Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and MelanomaActive, not recruitingNCT04478318Not applicable
• Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside SitesTerminatedNCT04474613Not applicable
• KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerStatus unknownNCT04474119Phase 3
• Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC PatientsStatus unknownNCT04473703
• Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).Active, not recruitingNCT04472949Phase 2
• A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2
• Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC PatientsWithdrawnNCT04470674Phase 2
• Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating MutationStatus unknownNCT04470076Phase 2
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerWithdrawnNCT04466917Phase 3
• Mobile Sensor Technologies to Assess General Symptomology of People With CancerCompletedNCT04465214
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
• Thoracic RadiothErapy with Atezolizumab in Small Cell LUng CanceR Extensive DiseaseCompletedNCT04462276Phase 2
• A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
• JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.Status unknownNCT04459663Phase 2
• Multimodality Treatment Including Curative Resection of Advanced NSCLCStatus unknownNCT04455984
• Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.Status unknownNCT04453423Phase 2
• Effect of Hyponatremia in Small Cell Lung CancerCompletedNCT04451460
• Pulmonary and Extrapulmonary Impairments in Patients With Lung Cancer Awaiting SurgeryCompletedNCT04450719
• Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerStatus unknownNCT04448379Phase 1
• ENB Vs. Conventional Bronchoscopy With Fluoroscopy for Safe and Effective Biopsy of Pulmonary LesionsStatus unknownNCT04447482Not applicable
• Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer TreatmentStatus unknownNCT04440800
• A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Phase 3
• IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerCompletedNCT04434482Phase 1/2
• Effect of Incidental Findings Information on Lung Cancer Screening IntentCompletedNCT04432753Not applicable
• Assessment of Functional Capacity, Pain, Cognitive and Respiratory Functions in Lung Cancer SurvivorsCompletedNCT04431921
• A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLCWithdrawnNCT04430933Phase 1/2
• Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME StudyActive, not recruitingNCT04430725
• Immune Checkpoint Inhibitors and Atherosclerotic Plaque VolumeCompletedNCT04430712
• Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal CancerActive, not recruitingNCT04428905Phase 3
• Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerStatus unknownNCT04425681Phase 2
• Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLCStatus unknownNCT04425135Phase 2
• Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung CancerTerminatedNCT04422392Phase 2
• Detecting Lung Cancer Based on Exhaled BreathCompletedNCT04419207
• ESCAP-2020-CPHG: Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort PatientsStatus unknownNCT04419155
• Bronchoscopy Screening for High-risk Population of Lung Cancer With Severe Smoking With Negative LDCT ScreenStatus unknownNCT04413669Not applicable
• cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation OperationStatus unknownNCT04413656Not applicable
• Study of the Immunity of Patients With Lung Cancer and COVID-19 InfectionCompletedNCT04407143
• A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung CancerStatus unknownNCT04404543Phase 1
• A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerStatus unknownNCT04398940Phase 2
• Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung CancerStatus unknownNCT04397926Phase 1
• Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901Status unknownNCT04396457Phase 2
• The Role of 18F-FDG-PET/CT Scan in Lung Cancer PatientsStatus unknownNCT04395651
• Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyActive, not recruitingNCT04392505Phase 2
• Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 InsertionsStatus unknownNCT04382300Phase 2
• Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung CancerCompletedNCT04381910Phase 2
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3
• Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04379739Phase 2
• Progressive Web App About Individualized Patient Decision Aid for NSCLC Stage I-IIStatus unknownNCT04375566
• Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLCStatus unknownNCT04372732
• Microwave Ablation of Primary and Secondary Lung MalignanciesStatus unknownNCT04369872Phase 1/2
• Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)Active, not recruitingNCT04367311Phase 2
• Iraqi Trial for Lung Cancer ScreeningStatus unknownNCT04366661Not applicable
• Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung CancerStatus unknownNCT04366219
• Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.Active, not recruitingNCT04364776
• Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsCompletedNCT04361825Phase 2
• Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04356118Phase 4
• Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 InhibitorsStatus unknownNCT04355806
• COM902 (A TIGIT Inhibitor) in Subjects With Advanced MalignanciesCompletedNCT04354246Phase 1
• Impact of Robotic Approach Compared to VATS and Open Approach on Quality of Life in Patients With Lung CancerStatus unknownNCT04353349

← Lung Neoplasms overview